社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
艾迪康控股(09860)
4.540
-0.100
-2.16%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
Tom是龙呀
·
02-27
$艾迪康控股(09860)$
聊到大健康赛道,就不得不提艾迪康。说白了,它就是大健康领域里搞医学检验的头部玩家,原本靠给医院做专业化验起家,现在不光把老本行做透了,还靠着 “检验 + 新药研发” 双轮驱动,再加 AI 和数字化的 buff,往大健康的全链条都扎进去了,越做越全能。
$艾迪康控股(09860)$ 聊到大健康赛道,就不得不提艾迪康。说白了,它就是大健康领域里搞医学检验的头部玩家,原本靠给医院做专业化验起家,现在不光把老本...
回复
评论
点赞
1
编组 21备份 2
分享
举报
虎哥爱老虎油
·
02-10
$艾迪康控股(09860)$
$阿里健康(00241)$
AI 医疗与大健康,顺应时代大势,长期成长趋势确定,未来前景广阔。
$艾迪康控股(09860)$ $阿里健康(00241)$ AI 医疗与大健康,顺应时代大势,长期成长趋势确定,未来前景广阔。
回复
评论
点赞
1
编组 21备份 2
分享
举报
今晚去边到玩
·
02-06
$艾迪康控股(09860)$
股价已经逐步平稳了,年后必定会爆发一波行情!
$艾迪康控股(09860)$ 股价已经逐步平稳了,年后必定会爆发一波行情!
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
我要贴贴
·
01-30
$艾迪康控股(09860)$
艾迪康×迈瑞共建共赢!聚焦区域检验中心、供应链共享,推动优质医检资源下沉,助力分级诊疗落地生根
$艾迪康控股(09860)$ 艾迪康×迈瑞共建共赢!聚焦区域检验中心、供应链共享,推动优质医检资源下沉,助力分级诊疗落地生根
回复
评论
点赞
1
编组 21备份 2
分享
举报
今晚去边到玩
·
01-23
$艾迪康控股(09860)$
现在的市场就是典型慢牛!涨涨跌跌但整体向上,别想着一口吃成胖子,平常心拿捏就对了
$艾迪康控股(09860)$ 现在的市场就是典型慢牛!涨涨跌跌但整体向上,别想着一口吃成胖子,平常心拿捏就对了
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
DC资讯
·
01-26
富瑞金融:看好艾迪康 (09860) AI 战略布局和 Crown Bioscience 并购 予以 “买入” 评级目标价看高至 12.6 港元
智通财经 APP 获悉,富瑞金融发表研报,给予艾迪康控股 (09860)“买入” 评级,目标价为 12.60 港元。该行表示,艾迪康在 AI 医疗检测领域的战略布局及拟收购 Crown Bioscience 的重大举措,将显著强化公司在药物研发与诊断价值链中的综合实力。 报告指出,艾迪康的 AI 战略围绕三大支柱展开:其一,AI 辅助病理阅片系统能将切片读取效率提升至人工的 6-7 倍,并具备自动识别和纠正报告中的笔误、解剖部位错误及诊断遗漏的质量控制功能。其二,公司推出了面向临床医生的生成式 AI 实验室助手 “艾小医” 以及与**联合开发的临床大语言模型 “问医”,这些工具已整合到诊疗工作流程中,服务于报告质控、流式细胞分析及患者智能诊断门户。其三,艾迪康已完成了其长达 20 年的精准医学检测数据的阶段性质整合、治理与清洗,并正积极探索其在商业保险等领域的商业化机会。公司目前每年完成约 1000 万次 AI 辅助影像解读。 值得注意的是,艾迪康于 2025 年 11 月宣布以最高 2.04 亿美元的对价收购 Crown Bioscience。该交易包括 1.2 亿美元的首期付款及基于业绩目标的递延支付。据了解,Crown Bioscience 专注于转化肿瘤学与免疫肿瘤学领域,拥有全球最大的商业 PDX 模型库,在 CDX 模型及生物标志物解决方案领域具备深厚积累,服务于全球 1100 余家客户 (含全球前 20 大制药企业)。此外,Crown 在 AI 领域布局领先,拥有行业首个临床前数据平台及先进的抗癌药物协同预测工具。 富瑞金融认为,此次收购将大幅提升艾迪康在临床前及转化研究方面的能力,并通过 Crown 丰富的数据资产和生物信息学专长进一步巩固其行业地位。交易完成后,预计艾迪康约 23% 的收入将来自海外市场。
富瑞金融:看好艾迪康 (09860) AI 战略布局和 Crown Bioscience 并购 予以 “买入” 评级目标价看高至 12.6 港元
回复
评论
点赞
1
编组 21备份 2
分享
举报
我要贴贴
·
01-20
$艾迪康控股(09860)$
2026年AI应用元年,AI医疗必还有行情,回调即是买入的机会。
$艾迪康控股(09860)$ 2026年AI应用元年,AI医疗必还有行情,回调即是买入的机会。
回复
评论
点赞
1
编组 21备份 2
分享
举报
艾迪康
·
01-30
强强联合!艾迪康与迈瑞医疗签署全面战略协议,共筑智慧医检新生态
当前,在医保控费趋严、行业集中度提升的背景下,AI与数智技术正加速渗透,独立医学实验室(ICL)行业步入深度整合与转型的关键期。与此同时,国家正持续推进分级诊疗、加强基层医疗服务能力建设,并鼓励第三方医学检验机构与国产高端医疗器械企业协同发展。在此背景下,中国第三方医检行业的先行者企业艾迪康,与全球高科技的医疗器械与解决方案供应商迈瑞医疗再度携手,于1月27日举行战略合作签约仪式,正式签署《全面深化战略合作框架协议》。双方旨在通过资源整合、模式创新与技术融合,共同构建面向未来的智慧医检新生态。 艾迪康与迈瑞医疗双方核心管理层共同出席了本次签约仪式。根据正式签署的《战略合作框架协议》,双方将以平等互利、优势互补为原则,建立长期稳定的战略合作关系,重点围绕区域检验中心共建、医院检验实验室共建及供应链资源共享等方面开展多元协作,共同推广先进医学检验技术与管理模式,共享专家、临床与学术资源,并通过提升基层医疗机构检验服务能力,积极促进分级诊疗制度的落地实施。 ▲会议现场 此次合作中,艾迪康重点强调了其“AI+医疗”的战略布局。作为在AI医疗领域已取得实质性进展的企业,艾迪康不仅通过自研AI模型提升运营效率,还与**云联合发布了“问医”大模型。基于此技术积累,艾迪康将与迈瑞共同聚焦“AI+检验”的融合创新,携手研发面向医院场景的定制化智慧检验解决方案与产品,推动检验服务向智能化、精准化全面升级,并为未来在智慧医院、数字化生态等更广阔领域的协同奠定基础。 在签约仪式上,迈瑞集团总裁吴昊在致辞中表示期待与艾迪康通过共建模式推动优质检验资源下沉,共同打造可持续的医检服务新模式。艾迪康董事长杨凌表示,面对行业变革,艾迪康始终坚持创新与质量并重,持续优化业务布局,并对与迈瑞未来的深度合作充满期待。艾迪康执行董事、首席执行官高嵩进一步指出,艾迪康与迈瑞的合作,不仅能推
强强联合!艾迪康与迈瑞医疗签署全面战略协议,共筑智慧医检新生态
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
艾迪康
·
01-29
艾迪康深耕公益荣获双项大奖,以专业力量助力健康中国
当可持续发展成为全球共识,当商业向善成为时代命题,公益与ESG已成为推动社会进步的重要力量。1月22日至23日,第十五届公益节暨ESG影响力年会在北京隆重举行。作为中国公益领域颇具影响力与号召力的年度盛会,本届公益节以“15年,共益新篇章”为主题,汇聚了超过1200位公益、商业与学术各界代表,共同探讨公益与可持续发展的未来路径。在此盛会上,艾迪康凭借其在公益领域的持续深耕与突出贡献,成功斩获“医疗健康企业责任典范奖”,公司CEO高嵩同时获评“2025年度公益人物奖”。 ▲艾迪康荣获“医疗健康企业责任典范奖”、CEO高嵩荣膺“年度公益人物” 过去十四年,公益节见证了无数责任品牌的成长与公益项目的落地,超过3000家责任品牌、1000余位榜样人物参与奖项角逐,影响力覆盖超8000万人次。而艾迪康作为医疗健康领域的优秀代表,始终积极投身公益事业,留下了诸多温暖且有力的足迹。 ▲会议现场 艾迪康此次获奖的“宫颈癌科普宣教公益行”项目,是与中国妇幼保健协会深度合作的典范之作。该项目启动至今,足迹已遍布浙江、江西、山东、福建、湖北、四川、吉林、辽宁等多个省份,通过多层次学术交流与科普活动,有效提升了基层医疗机构的宫颈癌诊疗水平。事实上,艾迪康自2009年国家“两癌筛查”项目启动之初便持续投身其中,不仅承担了大量宫颈癌检测工作,更在技术、服务等多个维度为全国各地筛查项目提供全力支持。这一持续十余年的坚守,正是艾迪康“每一个样本都是一个生命”价值观的现实映照。 ▲“宫颈癌科普宣教公益行”现场照片 另一获奖项目“守护星行动”则展现了艾迪康对特殊群体的温暖关怀。在今年腾讯“99公益日”期间,艾迪康携手浙江省妇女儿童基金会发起孤独症儿童关爱募捐,在CEO高嵩及管理层的号召下,活动登上腾讯公益首页,短短数日便获得百余位爱心人士支持,形成“企业带动
艾迪康深耕公益荣获双项大奖,以专业力量助力健康中国
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
艾迪康
·
01-29
捷报+1!艾迪康旗下上海锦测通过上海临检质控中心2025年下呼吸道tNGS室间质评!
下呼吸道感染是全球感染性死亡的主要病因之一,涵盖气管炎、支气管炎、肺炎等多种疾病,其病原体复杂多样,且具有高发病率与高病死率的严峻挑战。传统检测方法在检出率与时效性上存在局限,尤其在应对微量病原或混合感染时,往往难以实现精准鉴别,影响重症患者的诊疗效率。随着临床对病原学诊断要求的提升,靶向高通量测序(tNGS)技术凭借其高灵敏度、快速检测周期和良好的成本效益,成为下呼吸道病原诊断的重要工具。该技术具有覆盖广、速度快、准确性高的综合优势,可同步检测细菌、病毒、真菌、支原体等多种病原体,从而为临床精准用药与提升诊疗效率提供关键技术支撑[1]。 为系统评估各实验室的检测能力,上海市临床检验质量控制中心于2025年组织开展下呼吸道感染病原体tNGS检测室间质量评价。本次活动共有全国83家单位参与,通过对10份不同浓度盲样样本的检测,综合评价了各机构在病原检测中的灵敏度、特异性与准确性。该评价体系严谨全面,涵盖检测灵敏度、特异性、稳定性及混合感染识别能力等多维指标,被视为检验医学领域实验室技术能力的“试金石”。 经过严格评审,艾迪康旗下上海锦测医学检验所在本次室间质评中顺利通过,检测能力再获权威认可!上海锦测依托高质量的tNGS检测技术平台以及贯穿检测全流程的标准化质控体系,在有效控制假阳性与假阴性结果方面表现突出,圆满完成了精准识别能力的考核。 ▲艾迪康旗下上海锦测获上海市临检中心tNGS室间质评权威认证 本次质评聚焦常见及高致病性呼吸道感染病原体,从假阳性、假阴性及结果稳健性三大维度,评估参评实验室tNGS检测的特异性、灵敏度与稳定性。考核样本共10份,涉及肺炎链球菌、流感嗜血杆菌、热带念珠菌、甲型流感病毒、结核分枝杆菌、肺炎支原体等15种临床常见病原体,覆盖细菌、真菌、病毒、支原体等多个类别。样本浓度跨越10至10000 copies/mL,其中包含低至10 c
捷报+1!艾迪康旗下上海锦测通过上海临检质控中心2025年下呼吸道tNGS室间质评!
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
艾迪康控股
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.adicon.com.cn
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
艾迪康控股有限公司是一家主要提供独立医学实验室(ICL)的控股公司。该公司提供医学检验、临床试验、科研服务、健康管理及病理会诊服务。该公司重点发展感染性疾病、妇女健康、实体肿瘤、围产&儿童中心、血液等核心疾病领域,覆盖内科、儿科、妇产科、肿瘤科、神经科等众多科目。
2025-09-04
半年度报告
2025 中期报告
2025 中期报告
2025-08-22
半年度报告
截至2025年6月30日止六个月之中期业绩公告
截至2025年6月30日止六个月之中期业绩公告
2025-05-23
须予披露的交易
补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权
补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权
2025-05-06
须予披露的交易
须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权
须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权
2025-05-05
股份购回
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告
2025-04-25
年度报告
2024 年度报告
2024 年度报告
2025-03-31
年度报告
截至2024年12月31日止年度之年度业绩公告
截至2024年12月31日止年度之年度业绩公告
2024-09-19
半年度报告
2024 中期报告
2024 中期报告
2024-08-30
半年度报告
截至2024年6月30日止六个月之中期业绩公告
截至2024年6月30日止六个月之中期业绩公告
2024-04-29
股份购回
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告
2024-04-29
年度报告
2023 年度报告
2023 年度报告
2024-03-28
年度报告
截至2023年12月31日止年度之年度业绩公告
截至2023年12月31日止年度之年度业绩公告
2023-09-25
半年度报告
2023 中期报告
2023 中期报告
2023-08-23
半年度报告
截至2023年6月30日止六个月之中期业绩公告
截至2023年6月30日止六个月之中期业绩公告
2023-06-19
股份发售
绿色申请表格
绿色申请表格
分时
5日
日
周
月
数据加载中...
最高
4.850
今开
4.750
量比
1.20
最低
4.480
昨收
4.640
换手率
0.30%
热议股票
{"pagemeta":{"title":"艾迪康控股(09860)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪康控股(09860)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪康控股,09860,艾迪康控股股票,艾迪康控股股票老虎,艾迪康控股股票老虎国际,艾迪康控股行情,艾迪康控股股票行情,艾迪康控股股价,艾迪康控股股市,艾迪康控股股票价格,艾迪康控股股票交易,艾迪康控股股票购买,艾迪康控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪康控股(09860)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪康控股(09860)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"09860","data":{"stockData":{"symbol":"09860","market":"HK","secType":"STK","nameCN":"艾迪康控股","latestPrice":4.54,"timestamp":1772698105010,"preClose":4.64,"halted":0,"volume":2177000,"delay":0,"changeRate":-0.02155172413793096,"floatShares":726000000,"shares":726000000,"eps":0.07375597283981511,"marketStatus":"已收盘","change":-0.1,"latestTime":"03-05 16:08:25","open":4.75,"high":4.85,"low":4.48,"amount":10024578,"amplitude":0.079741,"askPrice":4.55,"askSize":34500,"bidPrice":4.53,"bidSize":17000,"shortable":3,"etf":0,"ttmEps":-0.043334873520970346,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"listingDate":1688054400000,"exchange":"SEHK","adjPreClose":4.64,"openAndCloseTimeList":[[1772674200000,1772683200000],[1772686800000,1772697600000]],"volumeRatio":1.203627,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.537243722805320","cardData":[{"tweetId":"537243722805320","author":{"authorId":"4214309262754792","idStr":"4214309262754792","name":"Tom是龙呀","avatar":"https://static.tigerbbs.com/d1e7571bf4f3b8e1d989f715e95ebc58","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>聊到大健康赛道,就不得不提艾迪康。说白了,它就是大健康领域里搞医学检验的头部玩家,原本靠给医院做专业化验起家,现在不光把老本行做透了,还靠着 “检验 + 新药研发” 双轮驱动,再加 AI 和数字化的 buff,往大健康的全链条都扎进去了,越做越全能。","plainDigest":"$艾迪康控股(09860)$ 聊到大健康赛道,就不得不提艾迪康。说白了,它就是大健康领域里搞医学检验的头部玩家,原本靠给医院做专业化验起家,现在不光把老本行做透了,还靠着 “检验 + 新药研发” 双轮驱动,再加 AI 和数字化的 buff,往大健康的全链条都扎进去了,越做越全能。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772183900213,"gmtModify":1772183902967,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":120,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/537243722805320","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":236,"displayRows":4,"foldSize":0,"authorId":"4214309262754792"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.531218534879696","cardData":[{"tweetId":"531218534879696","author":{"authorId":"4214309434755002","idStr":"4214309434755002","name":"虎哥爱老虎油","avatar":"https://static.tigerbbs.com/90161930b2951996910520cfe45ee4d5","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a><a href=\"https://laohu8.com/S/00241\">$阿里健康(00241)$ </a>AI 医疗与大健康,顺应时代大势,长期成长趋势确定,未来前景广阔。","plainDigest":"$艾迪康控股(09860)$ $阿里健康(00241)$ AI 医疗与大健康,顺应时代大势,长期成长趋势确定,未来前景广阔。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770712997667,"gmtModify":1770712999700,"symbols":["00241","09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":379,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/531218534879696","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":94,"displayRows":4,"foldSize":0,"authorId":"4214309434755002"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.529809486112456","cardData":[{"tweetId":"529809486112456","author":{"authorId":"4214309050754582","idStr":"4214309050754582","name":"今晚去边到玩","avatar":"https://static.tigerbbs.com/42bdd06ef5297ee59f855e899a0493b6","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>股价已经逐步平稳了,年后必定会爆发一波行情!","plainDigest":"$艾迪康控股(09860)$ 股价已经逐步平稳了,年后必定会爆发一波行情!","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770367140587,"gmtModify":1770367142621,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":325,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/529809486112456","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":61,"displayRows":4,"foldSize":0,"authorId":"4214309050754582"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.527355955499224","cardData":[{"tweetId":"527355955499224","author":{"authorId":"4214309196754722","idStr":"4214309196754722","name":"我要贴贴","avatar":"https://static.tigerbbs.com/8479ad8e76a5fd8994fed9af7fabbb2b","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>艾迪康×迈瑞共建共赢!聚焦区域检验中心、供应链共享,推动优质医检资源下沉,助力分级诊疗落地生根","plainDigest":"$艾迪康控股(09860)$ 艾迪康×迈瑞共建共赢!聚焦区域检验中心、供应链共享,推动优质医检资源下沉,助力分级诊疗落地生根","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769769973523,"gmtModify":1769769975457,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":575,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/527355955499224","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":108,"displayRows":4,"foldSize":0,"authorId":"4214309196754722"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.524839265760264","cardData":[{"tweetId":"524839265760264","author":{"authorId":"4214309050754582","idStr":"4214309050754582","name":"今晚去边到玩","avatar":"https://static.tigerbbs.com/42bdd06ef5297ee59f855e899a0493b6","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>现在的市场就是典型慢牛!涨涨跌跌但整体向上,别想着一口吃成胖子,平常心拿捏就对了","plainDigest":"$艾迪康控股(09860)$ 现在的市场就是典型慢牛!涨涨跌跌但整体向上,别想着一口吃成胖子,平常心拿捏就对了","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769161189971,"gmtModify":1769161192381,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":378,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/524839265760264","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":96,"displayRows":4,"foldSize":0,"authorId":"4214309050754582"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.525870369722648","cardData":[{"tweetId":"525870369722648","author":{"authorId":"4197978151296510","idStr":"4197978151296510","name":"DC资讯","avatar":"https://static.tigerbbs.com/066bc0133f5943170b20233dba6398d9","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"富瑞金融:看好艾迪康 (09860) AI 战略布局和 Crown Bioscience 并购 予以 “买入” 评级目标价看高至 12.6 港元","digest":"智通财经 APP 获悉,富瑞金融发表研报,给予艾迪康控股 (09860)“买入” 评级,目标价为 12.60 港元。该行表示,艾迪康在 AI 医疗检测领域的战略布局及拟收购 Crown Bioscience 的重大举措,将显著强化公司在药物研发与诊断价值链中的综合实力。 报告指出,艾迪康的 AI 战略围绕三大支柱展开:其一,AI 辅助病理阅片系统能将切片读取效率提升至人工的 6-7 倍,并具备自动识别和纠正报告中的笔误、解剖部位错误及诊断遗漏的质量控制功能。其二,公司推出了面向临床医生的生成式 AI 实验室助手 “艾小医” 以及与**联合开发的临床大语言模型 “问医”,这些工具已整合到诊疗工作流程中,服务于报告质控、流式细胞分析及患者智能诊断门户。其三,艾迪康已完成了其长达 20 年的精准医学检测数据的阶段性质整合、治理与清洗,并正积极探索其在商业保险等领域的商业化机会。公司目前每年完成约 1000 万次 AI 辅助影像解读。 值得注意的是,艾迪康于 2025 年 11 月宣布以最高 2.04 亿美元的对价收购 Crown Bioscience。该交易包括 1.2 亿美元的首期付款及基于业绩目标的递延支付。据了解,Crown Bioscience 专注于转化肿瘤学与免疫肿瘤学领域,拥有全球最大的商业 PDX 模型库,在 CDX 模型及生物标志物解决方案领域具备深厚积累,服务于全球 1100 余家客户 (含全球前 20 大制药企业)。此外,Crown 在 AI 领域布局领先,拥有行业首个临床前数据平台及先进的抗癌药物协同预测工具。 富瑞金融认为,此次收购将大幅提升艾迪康在临床前及转化研究方面的能力,并通过 Crown 丰富的数据资产和生物信息学专长进一步巩固其行业地位。交易完成后,预计艾迪康约 23% 的收入将来自海外市场。","plainDigest":"智通财经 APP 获悉,富瑞金融发表研报,给予艾迪康控股 (09860)“买入” 评级,目标价为 12.60 港元。该行表示,艾迪康在 AI 医疗检测领域的战略布局及拟收购 Crown Bioscience 的重大举措,将显著强化公司在药物研发与诊断价值链中的综合实力。 报告指出,艾迪康的 AI 战略围绕三大支柱展开:其一,AI 辅助病理阅片系统能将切片读取效率提升至人工的 6-7 倍,并具备自动识别和纠正报告中的笔误、解剖部位错误及诊断遗漏的质量控制功能。其二,公司推出了面向临床医生的生成式 AI 实验室助手 “艾小医” 以及与**联合开发的临床大语言模型 “问医”,这些工具已整合到诊疗工作流程中,服务于报告质控、流式细胞分析及患者智能诊断门户。其三,艾迪康已完成了其长达 20 年的精准医学检测数据的阶段性质整合、治理与清洗,并正积极探索其在商业保险等领域的商业化机会。公司目前每年完成约 1000 万次 AI 辅助影像解读。 值得注意的是,艾迪康于 2025 年 11 月宣布以最高 2.04 亿美元的对价收购 Crown Bioscience。该交易包括 1.2 亿美元的首期付款及基于业绩目标的递延支付。据了解,Crown Bioscience 专注于转化肿瘤学与免疫肿瘤学领域,拥有全球最大的商业 PDX 模型库,在 CDX 模型及生物标志物解决方案领域具备深厚积累,服务于全球 1100 余家客户 (含全球前 20 大制药企业)。此外,Crown 在 AI 领域布局领先,拥有行业首个临床前数据平台及先进的抗癌药物协同预测工具。 富瑞金融认为,此次收购将大幅提升艾迪康在临床前及转化研究方面的能力,并通过 Crown 丰富的数据资产和生物信息学专长进一步巩固其行业地位。交易完成后,预计艾迪康约 23% 的收入将来自海外市场。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769412914948,"gmtModify":1769412919986,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":478,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/525870369722648","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1283,"displayRows":4,"foldSize":0,"authorId":"4197978151296510"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.523778570077224","cardData":[{"tweetId":"523778570077224","author":{"authorId":"4214309196754722","idStr":"4214309196754722","name":"我要贴贴","avatar":"https://static.tigerbbs.com/8479ad8e76a5fd8994fed9af7fabbb2b","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>2026年AI应用元年,AI医疗必还有行情,回调即是买入的机会。","plainDigest":"$艾迪康控股(09860)$ 2026年AI应用元年,AI医疗必还有行情,回调即是买入的机会。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1768902233904,"gmtModify":1768906411607,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":492,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/523778570077224","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":72,"displayRows":4,"foldSize":0,"authorId":"4214309196754722"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.527323494499736","cardData":[{"tweetId":"527323494499736","author":{"authorId":"4151027865885450","idStr":"4151027865885450","name":"艾迪康","avatar":"https://static.tigerbbs.com/894dcd837ee3c84e52e3a5e19e3d4f93","userType":5,"introduction":"艾迪康为中国三大ICL服务提供商之一,主要为医院及体检中心提供丰富的一流检验服务。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":556,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"强强联合!艾迪康与迈瑞医疗签署全面战略协议,共筑智慧医检新生态","digest":" 当前,在医保控费趋严、行业集中度提升的背景下,AI与数智技术正加速渗透,独立医学实验室(ICL)行业步入深度整合与转型的关键期。与此同时,国家正持续推进分级诊疗、加强基层医疗服务能力建设,并鼓励第三方医学检验机构与国产高端医疗器械企业协同发展。在此背景下,中国第三方医检行业的先行者企业艾迪康,与全球高科技的医疗器械与解决方案供应商迈瑞医疗再度携手,于1月27日举行战略合作签约仪式,正式签署《全面深化战略合作框架协议》。双方旨在通过资源整合、模式创新与技术融合,共同构建面向未来的智慧医检新生态。 艾迪康与迈瑞医疗双方核心管理层共同出席了本次签约仪式。根据正式签署的《战略合作框架协议》,双方将以平等互利、优势互补为原则,建立长期稳定的战略合作关系,重点围绕区域检验中心共建、医院检验实验室共建及供应链资源共享等方面开展多元协作,共同推广先进医学检验技术与管理模式,共享专家、临床与学术资源,并通过提升基层医疗机构检验服务能力,积极促进分级诊疗制度的落地实施。 ▲会议现场 此次合作中,艾迪康重点强调了其“AI+医疗”的战略布局。作为在AI医疗领域已取得实质性进展的企业,艾迪康不仅通过自研AI模型提升运营效率,还与**云联合发布了“问医”大模型。基于此技术积累,艾迪康将与迈瑞共同聚焦“AI+检验”的融合创新,携手研发面向医院场景的定制化智慧检验解决方案与产品,推动检验服务向智能化、精准化全面升级,并为未来在智慧医院、数字化生态等更广阔领域的协同奠定基础。 在签约仪式上,迈瑞集团总裁吴昊在致辞中表示期待与艾迪康通过共建模式推动优质检验资源下沉,共同打造可持续的医检服务新模式。艾迪康董事长杨凌表示,面对行业变革,艾迪康始终坚持创新与质量并重,持续优化业务布局,并对与迈瑞未来的深度合作充满期待。艾迪康执行董事、首席执行官高嵩进一步指出,艾迪康与迈瑞的合作,不仅能推","plainDigest":" 当前,在医保控费趋严、行业集中度提升的背景下,AI与数智技术正加速渗透,独立医学实验室(ICL)行业步入深度整合与转型的关键期。与此同时,国家正持续推进分级诊疗、加强基层医疗服务能力建设,并鼓励第三方医学检验机构与国产高端医疗器械企业协同发展。在此背景下,中国第三方医检行业的先行者企业艾迪康,与全球高科技的医疗器械与解决方案供应商迈瑞医疗再度携手,于1月27日举行战略合作签约仪式,正式签署《全面深化战略合作框架协议》。双方旨在通过资源整合、模式创新与技术融合,共同构建面向未来的智慧医检新生态。 艾迪康与迈瑞医疗双方核心管理层共同出席了本次签约仪式。根据正式签署的《战略合作框架协议》,双方将以平等互利、优势互补为原则,建立长期稳定的战略合作关系,重点围绕区域检验中心共建、医院检验实验室共建及供应链资源共享等方面开展多元协作,共同推广先进医学检验技术与管理模式,共享专家、临床与学术资源,并通过提升基层医疗机构检验服务能力,积极促进分级诊疗制度的落地实施。 ▲会议现场 此次合作中,艾迪康重点强调了其“AI+医疗”的战略布局。作为在AI医疗领域已取得实质性进展的企业,艾迪康不仅通过自研AI模型提升运营效率,还与**云联合发布了“问医”大模型。基于此技术积累,艾迪康将与迈瑞共同聚焦“AI+检验”的融合创新,携手研发面向医院场景的定制化智慧检验解决方案与产品,推动检验服务向智能化、精准化全面升级,并为未来在智慧医院、数字化生态等更广阔领域的协同奠定基础。 在签约仪式上,迈瑞集团总裁吴昊在致辞中表示期待与艾迪康通过共建模式推动优质检验资源下沉,共同打造可持续的医检服务新模式。艾迪康董事长杨凌表示,面对行业变革,艾迪康始终坚持创新与质量并重,持续优化业务布局,并对与迈瑞未来的深度合作充满期待。艾迪康执行董事、首席执行官高嵩进一步指出,艾迪康与迈瑞的合作,不仅能推","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769749236141,"gmtModify":1769749266752,"symbols":["09860"],"themeIds":["db24b339c29c488488c3af04b083adb3"],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/6f00c07a785ff5bb5ef08beca78ab0cc","width":"750","height":"500"},{"url":"https://static.tigerbbs.com/493d80135eebc815feda1c3fe0047780","width":"1080","height":"720"},{"url":"https://static.tigerbbs.com/597032d56528683a8bb02883c49aa6d8","width":"1080","height":"720"}],"repostCount":0,"viewCount":18898,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/527323494499736","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2459,"displayRows":4,"foldSize":0,"authorId":"4151027865885450"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.526848205931024","cardData":[{"tweetId":"526848205931024","author":{"authorId":"4151027865885450","idStr":"4151027865885450","name":"艾迪康","avatar":"https://static.tigerbbs.com/894dcd837ee3c84e52e3a5e19e3d4f93","userType":5,"introduction":"艾迪康为中国三大ICL服务提供商之一,主要为医院及体检中心提供丰富的一流检验服务。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":556,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"艾迪康深耕公益荣获双项大奖,以专业力量助力健康中国","digest":" 当可持续发展成为全球共识,当商业向善成为时代命题,公益与ESG已成为推动社会进步的重要力量。1月22日至23日,第十五届公益节暨ESG影响力年会在北京隆重举行。作为中国公益领域颇具影响力与号召力的年度盛会,本届公益节以“15年,共益新篇章”为主题,汇聚了超过1200位公益、商业与学术各界代表,共同探讨公益与可持续发展的未来路径。在此盛会上,艾迪康凭借其在公益领域的持续深耕与突出贡献,成功斩获“医疗健康企业责任典范奖”,公司CEO高嵩同时获评“2025年度公益人物奖”。 ▲艾迪康荣获“医疗健康企业责任典范奖”、CEO高嵩荣膺“年度公益人物” 过去十四年,公益节见证了无数责任品牌的成长与公益项目的落地,超过3000家责任品牌、1000余位榜样人物参与奖项角逐,影响力覆盖超8000万人次。而艾迪康作为医疗健康领域的优秀代表,始终积极投身公益事业,留下了诸多温暖且有力的足迹。 ▲会议现场 艾迪康此次获奖的“宫颈癌科普宣教公益行”项目,是与中国妇幼保健协会深度合作的典范之作。该项目启动至今,足迹已遍布浙江、江西、山东、福建、湖北、四川、吉林、辽宁等多个省份,通过多层次学术交流与科普活动,有效提升了基层医疗机构的宫颈癌诊疗水平。事实上,艾迪康自2009年国家“两癌筛查”项目启动之初便持续投身其中,不仅承担了大量宫颈癌检测工作,更在技术、服务等多个维度为全国各地筛查项目提供全力支持。这一持续十余年的坚守,正是艾迪康“每一个样本都是一个生命”价值观的现实映照。 ▲“宫颈癌科普宣教公益行”现场照片 另一获奖项目“守护星行动”则展现了艾迪康对特殊群体的温暖关怀。在今年腾讯“99公益日”期间,艾迪康携手浙江省妇女儿童基金会发起孤独症儿童关爱募捐,在CEO高嵩及管理层的号召下,活动登上腾讯公益首页,短短数日便获得百余位爱心人士支持,形成“企业带动","plainDigest":" 当可持续发展成为全球共识,当商业向善成为时代命题,公益与ESG已成为推动社会进步的重要力量。1月22日至23日,第十五届公益节暨ESG影响力年会在北京隆重举行。作为中国公益领域颇具影响力与号召力的年度盛会,本届公益节以“15年,共益新篇章”为主题,汇聚了超过1200位公益、商业与学术各界代表,共同探讨公益与可持续发展的未来路径。在此盛会上,艾迪康凭借其在公益领域的持续深耕与突出贡献,成功斩获“医疗健康企业责任典范奖”,公司CEO高嵩同时获评“2025年度公益人物奖”。 ▲艾迪康荣获“医疗健康企业责任典范奖”、CEO高嵩荣膺“年度公益人物” 过去十四年,公益节见证了无数责任品牌的成长与公益项目的落地,超过3000家责任品牌、1000余位榜样人物参与奖项角逐,影响力覆盖超8000万人次。而艾迪康作为医疗健康领域的优秀代表,始终积极投身公益事业,留下了诸多温暖且有力的足迹。 ▲会议现场 艾迪康此次获奖的“宫颈癌科普宣教公益行”项目,是与中国妇幼保健协会深度合作的典范之作。该项目启动至今,足迹已遍布浙江、江西、山东、福建、湖北、四川、吉林、辽宁等多个省份,通过多层次学术交流与科普活动,有效提升了基层医疗机构的宫颈癌诊疗水平。事实上,艾迪康自2009年国家“两癌筛查”项目启动之初便持续投身其中,不仅承担了大量宫颈癌检测工作,更在技术、服务等多个维度为全国各地筛查项目提供全力支持。这一持续十余年的坚守,正是艾迪康“每一个样本都是一个生命”价值观的现实映照。 ▲“宫颈癌科普宣教公益行”现场照片 另一获奖项目“守护星行动”则展现了艾迪康对特殊群体的温暖关怀。在今年腾讯“99公益日”期间,艾迪康携手浙江省妇女儿童基金会发起孤独症儿童关爱募捐,在CEO高嵩及管理层的号召下,活动登上腾讯公益首页,短短数日便获得百余位爱心人士支持,形成“企业带动","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769652756348,"gmtModify":1769652986037,"symbols":["09860"],"themeIds":["db24b339c29c488488c3af04b083adb3"],"popularizeThemeFlag":false,"imageCount":6,"images":[{"url":"https://static.tigerbbs.com/661c9244eedf6640865217d8b0f649c3","width":"750","height":"500"},{"url":"https://static.tigerbbs.com/868a639d942f78071b9ea4a398a9e56c","width":"750","height":"500"},{"url":"https://static.tigerbbs.com/60c28342211e3d1d17cbff7aab334849","width":"750","height":"500"}],"repostCount":0,"viewCount":18144,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/526848205931024","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2933,"displayRows":4,"foldSize":0,"authorId":"4151027865885450"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.526846556017816","cardData":[{"tweetId":"526846556017816","author":{"authorId":"4151027865885450","idStr":"4151027865885450","name":"艾迪康","avatar":"https://static.tigerbbs.com/894dcd837ee3c84e52e3a5e19e3d4f93","userType":5,"introduction":"艾迪康为中国三大ICL服务提供商之一,主要为医院及体检中心提供丰富的一流检验服务。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":556,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"捷报+1!艾迪康旗下上海锦测通过上海临检质控中心2025年下呼吸道tNGS室间质评!","digest":" 下呼吸道感染是全球感染性死亡的主要病因之一,涵盖气管炎、支气管炎、肺炎等多种疾病,其病原体复杂多样,且具有高发病率与高病死率的严峻挑战。传统检测方法在检出率与时效性上存在局限,尤其在应对微量病原或混合感染时,往往难以实现精准鉴别,影响重症患者的诊疗效率。随着临床对病原学诊断要求的提升,靶向高通量测序(tNGS)技术凭借其高灵敏度、快速检测周期和良好的成本效益,成为下呼吸道病原诊断的重要工具。该技术具有覆盖广、速度快、准确性高的综合优势,可同步检测细菌、病毒、真菌、支原体等多种病原体,从而为临床精准用药与提升诊疗效率提供关键技术支撑[1]。 为系统评估各实验室的检测能力,上海市临床检验质量控制中心于2025年组织开展下呼吸道感染病原体tNGS检测室间质量评价。本次活动共有全国83家单位参与,通过对10份不同浓度盲样样本的检测,综合评价了各机构在病原检测中的灵敏度、特异性与准确性。该评价体系严谨全面,涵盖检测灵敏度、特异性、稳定性及混合感染识别能力等多维指标,被视为检验医学领域实验室技术能力的“试金石”。 经过严格评审,艾迪康旗下上海锦测医学检验所在本次室间质评中顺利通过,检测能力再获权威认可!上海锦测依托高质量的tNGS检测技术平台以及贯穿检测全流程的标准化质控体系,在有效控制假阳性与假阴性结果方面表现突出,圆满完成了精准识别能力的考核。 ▲艾迪康旗下上海锦测获上海市临检中心tNGS室间质评权威认证 本次质评聚焦常见及高致病性呼吸道感染病原体,从假阳性、假阴性及结果稳健性三大维度,评估参评实验室tNGS检测的特异性、灵敏度与稳定性。考核样本共10份,涉及肺炎链球菌、流感嗜血杆菌、热带念珠菌、甲型流感病毒、结核分枝杆菌、肺炎支原体等15种临床常见病原体,覆盖细菌、真菌、病毒、支原体等多个类别。样本浓度跨越10至10000 copies/mL,其中包含低至10 c","plainDigest":" 下呼吸道感染是全球感染性死亡的主要病因之一,涵盖气管炎、支气管炎、肺炎等多种疾病,其病原体复杂多样,且具有高发病率与高病死率的严峻挑战。传统检测方法在检出率与时效性上存在局限,尤其在应对微量病原或混合感染时,往往难以实现精准鉴别,影响重症患者的诊疗效率。随着临床对病原学诊断要求的提升,靶向高通量测序(tNGS)技术凭借其高灵敏度、快速检测周期和良好的成本效益,成为下呼吸道病原诊断的重要工具。该技术具有覆盖广、速度快、准确性高的综合优势,可同步检测细菌、病毒、真菌、支原体等多种病原体,从而为临床精准用药与提升诊疗效率提供关键技术支撑[1]。 为系统评估各实验室的检测能力,上海市临床检验质量控制中心于2025年组织开展下呼吸道感染病原体tNGS检测室间质量评价。本次活动共有全国83家单位参与,通过对10份不同浓度盲样样本的检测,综合评价了各机构在病原检测中的灵敏度、特异性与准确性。该评价体系严谨全面,涵盖检测灵敏度、特异性、稳定性及混合感染识别能力等多维指标,被视为检验医学领域实验室技术能力的“试金石”。 经过严格评审,艾迪康旗下上海锦测医学检验所在本次室间质评中顺利通过,检测能力再获权威认可!上海锦测依托高质量的tNGS检测技术平台以及贯穿检测全流程的标准化质控体系,在有效控制假阳性与假阴性结果方面表现突出,圆满完成了精准识别能力的考核。 ▲艾迪康旗下上海锦测获上海市临检中心tNGS室间质评权威认证 本次质评聚焦常见及高致病性呼吸道感染病原体,从假阳性、假阴性及结果稳健性三大维度,评估参评实验室tNGS检测的特异性、灵敏度与稳定性。考核样本共10份,涉及肺炎链球菌、流感嗜血杆菌、热带念珠菌、甲型流感病毒、结核分枝杆菌、肺炎支原体等15种临床常见病原体,覆盖细菌、真菌、病毒、支原体等多个类别。样本浓度跨越10至10000 copies/mL,其中包含低至10 c","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769652384861,"gmtModify":1769653282171,"symbols":["09860"],"themeIds":["db24b339c29c488488c3af04b083adb3"],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/6a6450eb51746a62a6fdcc3774438a34","width":"1080","height":"641"}],"repostCount":0,"viewCount":18192,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/526846556017816","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3467,"displayRows":4,"foldSize":0,"authorId":"4151027865885450"}],"position":0}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20127229","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8qcU3XSpqb","pdf_url":"https://static.tigerbbs.com/48742dd21ddc4fa193bfbdfd4d403b24","pub_time":1756974720000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025 中期报告","symbol":"09860","title":"2025 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0904/2025090400592_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-04 16:32","pubTimestamp":1756974720,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20026291","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7W2RmXZjUH","pdf_url":"https://static.tigerbbs.com/cc976c038f4f4ea397060e6e41701a11","pub_time":1755851460000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2025年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0822/2025082200344_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-22 16:31","pubTimestamp":1755851460,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19687385","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7ySYFzjdR4","pdf_url":"https://static.tigerbbs.com/b814470e99bb4cfdbe1a02e64091a77b","pub_time":1747996320000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权","symbol":"09860","title":"补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0523/2025052301196_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 代价发行 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-05-23 18:32","pubTimestamp":1747996320,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19603677","market":"hk","labels":[],"media":"港交所","original_id":"N.HK3H853NAEbH","pdf_url":"https://static.tigerbbs.com/c06fe01de56f43f981b68567b705fc77","pub_time":1746528900000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权","symbol":"09860","title":"须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0506/2025050602420_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 代价发行 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-05-06 18:55","pubTimestamp":1746528900,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19597967","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEo8TY2XvmQ","pdf_url":"https://static.tigerbbs.com/7ca5dbae815b4e399fcf13655d0a1acc","pub_time":1746441240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告","symbol":"09860","title":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0505/2025050500020_c.pdf","us_notice_code":"通函 - [在股东批准的情况下重选或委任董事 / 回购股份的说明函件 / 一般性授权]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2025-05-05 18:34","pubTimestamp":1746441240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19491661","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEx9zzMSh1b","pdf_url":"https://static.tigerbbs.com/13ef2c62d20843a1ad97cdfe80faf8f1","pub_time":1745535660000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024 年度报告","symbol":"09860","title":"2024 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0425/2025042500092_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-25 07:01","pubTimestamp":1745535660,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19320874","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGB2fjFgogz","pdf_url":"https://static.tigerbbs.com/c18b5790e4a945cd8a12533a1b409d9c","pub_time":1743409920000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度之年度业绩公告","symbol":"09860","title":"截至2024年12月31日止年度之年度业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0331/2025033100496_c.pdf","us_notice_code":"公告及通告 - [末期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-31 16:32","pubTimestamp":1743409920,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18628725","market":"hk","labels":[],"media":"港交所","original_id":"N.HKG1TpP1gfaB","pdf_url":"https://static.tigerbbs.com/b16ec890af8f4624b7788927dbc5d2d1","pub_time":1726749240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024 中期报告","symbol":"09860","title":"2024 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0919/2024091901547_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-19 20:34","pubTimestamp":1726749240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18558369","market":"hk","labels":[],"media":"港交所","original_id":"N.HKB8e1fuRKXN","pdf_url":"https://static.tigerbbs.com/77908cbfff174581acabce1428a46a89","pub_time":1725006600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2024年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000546_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:30","pubTimestamp":1725006600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18049055","market":"hk","labels":[],"media":"港交所","original_id":"N.HKw1uprqHdc8","pdf_url":"https://static.tigerbbs.com/dad4dd4f1db641a4a59ebdeb33ab194b","pub_time":1714348800000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告","symbol":"09860","title":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042900166_c.pdf","us_notice_code":"通函 - [在股东批准的情况下重选或委任董事 / 回购股份的说明函件 / 一般性授权]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2024-04-29 08:00","pubTimestamp":1714348800,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18049017","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9L3M9jpzxE","pdf_url":"https://static.tigerbbs.com/c55bb1222fb44d99bd6ee8fbbcfede6c","pub_time":1714348560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2023 年度报告","symbol":"09860","title":"2023 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042900126_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2024-04-29 07:56","pubTimestamp":1714348560,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"17768188","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFEyBfD37aR","pdf_url":"https://static.tigerbbs.com/df8e2684de2045ffb13d01bff80e3432","pub_time":1711614600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2023年12月31日止年度之年度业绩公告","symbol":"09860","title":"截至2023年12月31日止年度之年度业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0328/2024032800753_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2024-03-28 16:30","pubTimestamp":1711614600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16998686","market":"hk","labels":[],"media":"港交所","original_id":"N.HKCMBjQGMKtn","pdf_url":"https://static.tigerbbs.com/b08e2368e8214fb7a91677f86fd55f29","pub_time":1695630660000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2023 中期报告","symbol":"09860","title":"2023 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0925/2023092500300_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2023-09-25 16:31","pubTimestamp":1695630660,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16837125","market":"hk","labels":[],"media":"港交所","original_id":"N.HKzEVQ86wd28","pdf_url":"https://static.tigerbbs.com/a8b6972dbfae4007ab808c01827b49be","pub_time":1692779400000,"showTitleType":false,"size":0,"source":"hk_ex_news","summary":"截至2023年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2023年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0823/2023082300282_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2023-08-23 16:30","pubTimestamp":1692779400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16588691","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEoRw2BQmXa","pdf_url":"https://static.tigerbbs.com/7a00380fc99a46f2b17d6143c3b178d6","pub_time":1687126740000,"showTitleType":false,"size":0,"source":"hk_ex_news","summary":"绿色申请表格","symbol":"09860","title":"绿色申请表格","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0619/2023061900008_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2023-06-19 06:19","pubTimestamp":1687126740,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.adicon.com.cn","stockEarnings":[{"period":"1week","weight":-0.072},{"period":"1month","weight":-0.0812},{"period":"3month","weight":-0.1212},{"period":"6month","weight":-0.3582},{"period":"1year","weight":-0.367},{"period":"ytd","weight":0.0969}],"compareEarnings":[{"period":"1week","weight":-0.0566},{"period":"1month","weight":-0.057},{"period":"3month","weight":-0.0265},{"period":"6month","weight":-0.0066},{"period":"1year","weight":0.1006},{"period":"ytd","weight":-0.0149}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾迪康控股有限公司是一家主要提供独立医学实验室(ICL)的控股公司。该公司提供医学检验、临床试验、科研服务、健康管理及病理会诊服务。该公司重点发展感染性疾病、妇女健康、实体肿瘤、围产&儿童中心、血液等核心疾病领域,覆盖内科、儿科、妇产科、肿瘤科、神经科等众多科目。","exchange":"SEHK","name":"艾迪康控股","nameEN":"ADICON HOLDINGS"},"aProfile":null}}}